246 related articles for article (PubMed ID: 27025608)
1. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
Shimizu T; Fukuoka K; Takeda M; Iwasa T; Yoshida T; Horobin J; Keegan M; Vaickus L; Chavan A; Padval M; Nakagawa K
Cancer Chemother Pharmacol; 2016 May; 77(5):997-1003. PubMed ID: 27025608
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Jones SF; Siu LL; Bendell JC; Cleary JM; Razak AR; Infante JR; Pandya SS; Bedard PL; Pierce KJ; Houk B; Roberts WG; Shreeve SM; Shapiro GI
Invest New Drugs; 2015 Oct; 33(5):1100-7. PubMed ID: 26334219
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
Saka H; Kitagawa C; Kogure Y; Takahashi Y; Fujikawa K; Sagawa T; Iwasa S; Takahashi N; Fukao T; Tchinou C; Landers D; Yamada Y
Invest New Drugs; 2017 Aug; 35(4):451-462. PubMed ID: 28070720
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
[TBL] [Abstract][Full Text] [Related]
7. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Soria JC; Gan HK; Blagden SP; Plummer R; Arkenau HT; Ranson M; Evans TR; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Dean E; Brown J; Gibson D; Peddareddigari V; Murray S; Nebot N; Mazumdar J; Swartz L; Auger KR; Fleming RA; Singh R; Millward M
Ann Oncol; 2016 Dec; 27(12):2268-2274. PubMed ID: 27733373
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.
Wakui H; Yamamoto N; Kitazono S; Mizugaki H; Nakamichi S; Fujiwara Y; Nokihara H; Yamada Y; Suzuki K; Kanda H; Akinaga S; Tamura T
Cancer Chemother Pharmacol; 2014 Jul; 74(1):15-23. PubMed ID: 24752449
[TBL] [Abstract][Full Text] [Related]
10. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
[TBL] [Abstract][Full Text] [Related]
12. The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Doi T; Fujiwara Y; Shitara K; Shimizu T; Yonemori K; Matsubara N; Ohno I; Kogawa T; Naito Y; Leopold L; Munteanu M; Yatsuzuka N; Han SR; Samkari A; Yamamoto N
Invest New Drugs; 2021 Feb; 39(1):152-162. PubMed ID: 32564277
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
Gordon MS; Ilaria R; de Alwis DP; Mendelson DS; McKane S; Wagner MM; Look KY; LoRusso PM
Cancer Chemother Pharmacol; 2013 Jan; 71(1):21-7. PubMed ID: 23228983
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
Nokihara H; Yamada Y; Fujiwara Y; Yamamoto N; Wakui H; Nakamichi S; Kitazono S; Inoue K; Harada A; Taube T; Takeuchi Y; Tamura T
Invest New Drugs; 2016 Feb; 34(1):66-74. PubMed ID: 26627079
[TBL] [Abstract][Full Text] [Related]
16. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.
Takahashi T; Boku N; Murakami H; Naito T; Tsuya A; Nakamura Y; Ono A; Machida N; Yamazaki K; Watanabe J; Ruiz-Garcia A; Imai K; Ohki E; Yamamoto N
Invest New Drugs; 2012 Dec; 30(6):2352-63. PubMed ID: 22249430
[TBL] [Abstract][Full Text] [Related]
18. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Kanteti R; Mirzapoiazova T; Riehm JJ; Dhanasingh I; Mambetsariev B; Wang J; Kulkarni P; Kaushik G; Seshacharyulu P; Ponnusamy MP; Kindler HL; Nasser MW; Batra SK; Salgia R
Cancer Biol Ther; 2018 Apr; 19(4):316-327. PubMed ID: 29303405
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Siu LL; Pili R; Duran I; Messersmith WA; Chen EX; Sullivan R; MacLean M; King S; Brown S; Reid GK; Li Z; Kalita AM; Laille EJ; Besterman JM; Martell RE; Carducci MA
J Clin Oncol; 2008 Apr; 26(12):1940-7. PubMed ID: 18421048
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]